Subscribe To

Price Alert Latest News Economic Calendar News

LEGN / Legend Biotech shares gain on multiple-myeloma drug sales

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, -0.20%, generated $117 million in sales in the second quarter. That represents a roughly 65% increase over the previous quarter, BMO Capital Markets analysts wrote in a research note Thursday, suggesting that the U.S. Food and Drug Administration has increased Carvykti's manufacturing cap. Read More

Demo Live Account See Partner Details

Content Topics

Legend

Biotech

Gain

Multiple

Myeloma

Drug

Sales

Multiple myeloma

Stock

LEGN

Posted: Jul 20 2023, 08:23

Author Name: Market Watch

LEGN News

By Seeking Alpha
August 21, 2023

Legend Biotech: Working On Supply Issues

Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykt

By Zacks Investment Research
August 14, 2023

Why Earnings Season Could Be Great for Legend Biotech (LEGN)

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

By Market Watch
July 20, 2023

Legend Biotech shares gain on multiple-myeloma drug sales

Shares of Legend Biotech Corp. LEGN, -1.00% gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collabor

By Zacks Investment Research
June 7, 2023

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multipl

By The Motley Fool
May 1, 2023

After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?

If everyone expects a stock to rise and buys it, eventually someone will be wrong. Legend Biotech's shares are up by quite a bit this year already.

By MarketBeat
April 25, 2023

Why Legend Biotech Stock Is Having Its Best Month Yet

Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-b

By Investors Business Daily
April 21, 2023

Legend Bio Hits Profit-Taking Zone After Reportedly Confirming Key Study Results

Legend reportedly confirmed the leaked results of its multiple myeloma study on Friday, leading LEGN stock to surge. The post Legend Bio Hits Profit-T

By Zacks Investment Research
April 20, 2023

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progressi

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.